CTRI/2019/05/019047招募中3 期
A Double Blind, Placebo- Controlled, Randomized Phase III Study of IPATASERTIB in combination with Paclitaxel As a treatment for patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple Negative Breast cancer or Hormone Receptor â?? Positive, HER2 â?? Negative Breast Cancer
F HoffmannLa Roche Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Informed Consent
- •Woman or man age 18 years and above
- •Inoperable locally advanced/metastatic breast cancer (LA/MBC), Histologically documented TNBC or HR+/HER2â?? adenocarcinoma and suitable for taxane monotherapy
- •At least 12 month disease-free interval from last chemotherapy/radiation treatment for early BC.
- •Eastern Cooperative Oncology Group Performance Status of 0 or 1
- •Life expectancy of at least 6 months
- •Measurable disease according to RECIST v1.1
- •formalin-fixed, paraffin-embedded tumor (FFPE) tissue, [PIK3CA/AKT1/PTEN-altered status and central ctDNA]
- •Adequate hematologic and organ function within 14 days before the first study treatment
- •Fasting total serum glucose <= 150Â mg/dL and HbA1C <=Â 7.5%,
排除标准
- •Active infection requiring systemic anti-microbial treatment, Known HIV infection, Active viral or other Hepatitis
- •New York Heart Association Class II, III, or IV heart failure, LVEF less than 50%
- •History of or known presence of brain or spinal cord metastases by CT/ MRI
- •Any previous chemotherapy for inoperable locally advanced or metastatic TNBC or HR+/HER2â?? adenocarcinoma of the breast
- •Uncontrolled pleural effusion, pericardial effusion, or ascites
- •History of or active Inflammatory bowel disease, Lung disease
- •Prior treatment with an AKT inhibitor (Prior PI3K or mTOR inhibitors are allowed)
- •No uncontrolled disease/unresolved toxicity or clinically relevant condition which may contraindicate use of an investigational drug
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination with Methotrexate compared to Methotrexate Alone in Patients with Rheumatoid ArthritisMedDRA version: 12.0Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2009-012953-39-BG4SC AG244
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination with Methotrexate compared to Methotrexate Alone in Patients with Rheumatoid ArthritisMedDRA version: 12.0Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2009-012953-39-CZ4SC AG244
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination with Methotrexate compared to Methotrexate Alone in Patients with Rheumatoid ArthritisRheumatoid ArthritisEUCTR2009-012953-39-PL4SC AG244
进行中（未招募）
1 期
A controlled study to assess the safety, tolerability, and effectiveness of the study drug, ISIS 426115, in patients with Type 2 Diabetes who are being treated with MetformiMedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2013-002172-40-ROIsis Pharmaceuticals, Inc.40
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of maintenance therapy with PankoMab-GEX TM after chemotherapy in patients with recurrent epithelial ovarian carcinoma.Recurrent Epithelial Ovarian CarcinomaMedDRA version: 16.0Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000931-28-ESGlycotope GmbH210